-
1.发明公开TREATMENT OF COCCIDIOSIS WITH INTRAMUSCULAR TRIAZINE COMPOSITIONS 有权UNG ON ON EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN
公开(公告)号：EP2928455A1
公开(公告)日：2015-10-14
申请号：EP13815401.8
申请日：2013-12-06
CPC分类号： A61K45/06 , A61K9/0019 , A61K9/10 , A61K31/53 , A61K31/7135 , A61K33/26 , A61K2300/00
摘要： The present invention relates to compositions and methods for treating coccidiosis in non-human mammals. More particularly, the invention relates to intramuscular compositions and methods for treating coccidiosis with a triazine.
摘要翻译： 本发明涉及在非人哺乳动物中治疗球虫病的组合物和方法。 更具体地，本发明涉及肌内组合物和用三嗪治疗球虫病的方法。
-
公开(公告)号：EP2349272B1
公开(公告)日：2019-01-16
申请号：EP09783801.5
申请日：2009-10-07
-
公开(公告)号：EP2928454A1
公开(公告)日：2015-10-14
申请号：EP13802596.0
申请日：2013-12-06
摘要： The invention also relates to improved methods for protecting non-human animals with triazine compounds by intramuscular or subcutaneous injection(s). The invention can be used with various triazines, such as toltrazuril, in different non-human animals such as a porcine, an ovine, a bovine, a canine, a feline, or an avian, for protecting them against infectious diseases, such as protozoan disorders.
摘要翻译： 本发明还涉及通过肌肉内或皮下注射用三嗪化合物保护非人动物的改进方法。 本发明可用于不同的非人类动物如猪，羊，牛，犬，猫科动物或禽类中的各种三嗪类，例如妥拉唑，用于保护它们免受感染性疾病如原生动物 障碍。
-
公开(公告)号：EP2789346A1
公开(公告)日：2014-10-15
申请号：EP13163299.4
申请日：2013-04-11
发明人： Sato, Takanori
IPC分类号： A61K39/12 , A61K39/385
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/385 , A61K2039/552 , A61K2039/6075 , C07K2319/02 , C12N7/00 , C12N2710/24021 , C12N2710/24043 , C12N2710/24122 , C12N2750/10022 , C12N2750/10034 , C12N2750/10071
摘要： The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
摘要翻译： 本发明涉及新型免疫原性多肽及其在疫苗组合物中的用途。 本发明还涉及表达多肽的核酸，载体和细胞及其用途。 本发明的多肽更具体地包含衍生自B5R基因的免疫原结构域和细胞膜寻址结构域。 本发明特别适用于生产用于非人类动物的疫苗，特别是针对PCV2感染的猪接种疫苗。
-
公开(公告)号：EP2598151A1
公开(公告)日：2013-06-05
申请号：EP11743497.7
申请日：2011-07-29
IPC分类号： A61K31/7048 , A61K45/06 , A61K9/00 , A61P33/10
CPC分类号： A61K31/7048 , A61K9/0024 , A61K45/06 , A61K2300/00
摘要： The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.
-
公开(公告)号：EP1731612B1
公开(公告)日：2011-08-17
申请号：EP05720839.9
申请日：2005-03-09
发明人： Okuda, Takashi , Saitoh, Shuji , Saeki, Sakiko
IPC分类号： C12N15/38 , C12N15/869 , A61K39/255 , A61K39/265 , C12N7/01
CPC分类号： C12N15/86 , A61K39/12 , A61K39/245 , A61K2039/5256 , C07K14/005 , C12N2710/16022 , C12N2710/16034 , C12N2710/16043 , C12N2710/16334
摘要： A recombinant herpesvirus having a DNA encoding a polypeptide which comprises 429 amino acids in the amino terminal side of a protein encoded by infective pharyngeal bronchitis virus gB gene or a polypeptide derived therefrom by deletion, addition or substitution of one or more amino acids (excluding infective pharyngeal bronchitis virus).
-
公开(公告)号：EP2598151B1
公开(公告)日：2018-12-26
申请号：EP11743497.7
申请日：2011-07-29
IPC分类号： A61K31/7048 , A61K45/06 , A61K9/00 , A61P33/10
CPC分类号： A61K31/7048 , A61K9/0024 , A61K45/06 , A61K2300/00
摘要： The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.
-
8.发明公开TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S) 审中-公开TRIAZINFORMULIERUNGEN MIT EINEM ZWEITEN WIRKSTOFF UND TENSIDEN
公开(公告)号：EP2928498A1
公开(公告)日：2015-10-14
申请号：EP13814855.6
申请日：2013-12-06
IPC分类号： A61K45/06 , A61K47/14 , A61K47/24 , A61K47/34 , A61K9/10 , A61P33/02 , A61K31/53 , A61K8/49 , A61Q17/00 , A61K8/04
CPC分类号： A61K31/53 , A61J1/2093 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K33/26 , A61K45/06 , A61K47/02 , A61P33/02 , A61K2300/00
摘要： The present invention is relative to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
摘要翻译： 本发明涉及包含与另一活性成分组合的三嗪族的至少一种活性成分和允许减少泡沫形成的特定化合物的新型组合物。 更具体地说，本发明涉及包含三嗪，铁络合物和一种或多种具有特定HLB的表面活性剂的水悬浮液形式的组合物。
-
公开(公告)号：EP4082524A1
公开(公告)日：2022-11-02
申请号：EP21200376.8
申请日：2013-12-06
摘要： The present invention is relative to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
-
公开(公告)号：EP2928454B1
公开(公告)日：2020-03-18
申请号：EP13802596.0
申请日：2013-12-06
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.014 秒)
